Krystal Biotech (STU:4KB) Cyclically Adjusted Book per Share: €19.39 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4KB Krystal Biotech Inc STU:4KB
62 GF Score
Price €294.40
GF Value €291.96
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Krystal Biotech Cyclically Adjusted Book per Share?

Krystal Biotech STU:4KB -1.64% 62 Cyclically Adjusted Book per Share is €19.39 as of Jun. 2026. GuruFocus rates STU:4KB with a GF Score™ of 62/100 and a GF Value™ of €291.96 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Krystal Biotech's adjusted book value per share for the three months ended in Jun. 2026 was €40.167. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €19.39 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-09-15), Krystal Biotech's current stock price is €294.40. Krystal Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €19.39. Krystal Biotech's Cyclically Adjusted PB Ratio of today is 15.19.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of Krystal Biotech was 16.83. The lowest was 14.65. And the median was 15.57.


Krystal Biotech  (STU:4KB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Krystal Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=294.40/19.385
=15.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of Krystal Biotech was 16.83. The lowest was 14.65. And the median was 15.57.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Krystal Biotech Cyclically Adjusted Book per Share Related Terms


Krystal Biotech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Cyclically Adjusted Book per Share Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 18.15

Krystal Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 17.78 18.63 19.39

STU:4KB vs AXSM, APGE, IONS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Krystal Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Cyclically Adjusted PB Ratio falls into.


STU:4KB
62GF Score
Krystal Biotech Inc STU:4KB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Krystal Biotech's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=40.167/333.9520*333.9520
=40.167

Current CPI (Jun. 2026) = 333.9520.

Krystal Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.000 241.428 0.000
201612 -0.103 241.432 -0.142
201703 -0.139 243.801 -0.190
201706 -0.191 244.955 -0.260
201709 4.148 246.819 5.612
201712 3.997 246.524 5.415
201803 3.738 249.554 5.002
201806 3.745 251.989 4.963
201809 4.101 252.439 5.425
201812 6.865 251.233 9.125
201903 6.751 254.202 8.869
201906 10.276 256.143 13.398
201909 11.005 256.759 14.314
201912 10.416 256.974 13.536
202003 10.408 258.115 13.466
202006 14.022 257.797 18.164
202009 13.056 260.280 16.751
202012 12.109 260.474 15.525
202103 16.502 264.877 20.805
202106 15.894 271.696 19.536
202109 15.840 274.310 19.284
202112 20.706 278.802 24.802
202203 19.565 287.504 22.726
202206 20.841 296.311 23.488
202209 21.471 296.808 24.158
202212 18.993 296.797 21.371
202303 17.468 301.836 19.327
202306 21.399 305.109 23.422
202309 25.324 307.789 27.477
202312 24.963 306.746 27.177
202403 25.941 312.332 27.737
202406 27.264 314.175 28.980
202409 27.601 315.301 29.234
202412 31.740 315.605 33.585
202503 31.543 319.799 32.939
202506 30.647 322.561 31.729
202509 33.412 324.800 34.353
202512 35.572 324.054 36.659
202603 37.642 330.213 38.068
202606 40.167 333.952 40.167

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €19.39 mean?
Krystal Biotech (STU:4KB) has a Cyclically Adjusted Book per Share of €19.39 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's Cyclically Adjusted Book per Share too high?
Krystal Biotech's current Cyclically Adjusted Book per Share is €19.39. Overall, Krystal Biotech has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Cyclically Adjusted Book per Share compare to AXSM and APGE?
Krystal Biotech's Cyclically Adjusted Book per Share of €19.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Cyclically Adjusted Book per Share is €19.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (STU:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €291.96, compared to a current price of €294.40 — trading 0.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is €19.39. Krystal Biotech's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Krystal Biotech (STU:4KB), the current Cyclically Adjusted Book per Share is €19.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (STU:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €294.40 is trading 0.8% above its estimated GF Value™ of €291.96. GuruFocus considers Krystal Biotech to be Fairly Valued.

Key valuation signals for STU:4KB:

  • Cyclically Adjusted Book per Share: €19.39
  • GF Value™: €291.96 vs. price of €294.40 (0.8% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the STU:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Other Exchanges KRYS:USA1KRYS:Italy
Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
62GF Score

Get the complete analysis for STU:4KB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€294.40
Price
€291.96
GF Value